The global Adalimumab Drug Market was valued at approximately USD 17.7 billion in 2024 and is projected to reach USD 22.1 billion by 2032, registering a CAGR of 2.8% during the forecast period. The increasing prevalence of autoimmune and inflammatory diseases, expanding adoption of biologic therapies, and rising demand for advanced treatment options are driving sustained market growth...